BridgeBio Pharma: Emerging Rare Disease Leader With Robust Growth Outlook and Discounted Valuation Supporting Buy Rating

BridgeBio Pharma (BBIO) has received a new Buy rating, initiated by Morgan Stanley analyst, Sean Laaman.

Sean Laaman has given his Buy rating due to a combination of factors that underscore BridgeBio Pharma’s attractive growth and valuation profile. He views the company as emerging into a leading rare and genetic disease franchise, anchored by its commercial asset Attruby (acoramidis) in ATTR-CM and a broad, late-stage pipeline. His forecasts call for robust top-line growth through 2030, outpacing expected expense growth and driving a transition to positive net income and free cash flow by 2027, which supports the case that BBIO could evolve from a small/mid-cap into a much larger biopharma player. From a valuation standpoint, his discounted cash flow analysis supports a $96 price target, implying more than 20% upside and a 2030 price-to-earnings multiple well below that of large-cap peers, which he interprets as a compelling long-term entry point for investors.
In addition, Laaman’s projections for key products are generally more optimistic than the market’s, reflecting his confidence in the company’s clinical data and commercial potential. He models peak sales for Attruby in ATTR-CM at about $3.8 billion, ahead of consensus, and anticipates meaningful, risk-adjusted revenue contributions from infigratinib, encaleret, and BBP-418, particularly in rare skeletal and endocrine disorders. While he acknowledges risks, such as potential earlier-than-expected generic competition to rival therapies that could weigh on pricing and market share, he judges these uncertainties as manageable relative to the upside. Overall, the combination of a differentiated pipeline, strong expected revenue growth, and discounted valuation underpins his Overweight/Buy recommendation on BridgeBio Pharma.

According to TipRanks, Laaman is a 4-star analyst with an average return of 10.6% and a 63.39% success rate. Laaman covers the Healthcare sector, focusing on stocks such as Jazz Pharmaceuticals, Exelixis, and Neurocrine.

In another report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $85.00 price target.